Cost-Effectiveness of Ponatinib in The Treatment of Patients with Acute Lymphoblastic Leukemia with Philadelphia Chromosome Positive (PH+ ALL), Suitable for Allogeneic Stem Cell Transplant, in Greece

OBJECTIVES: To evaluate the cost-effectiveness of ponatinib over induction chemotherapy (IC), for the treatment of patients with Acute Lymphoblastic Leukemia with Philadelphia chromosome positive (Ph+ ALL) who exhibit resistance or intolerance (R/I) to dasatinib, or have the T315I mutation and are s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2017-10, Vol.20 (9), p.A438-A439
Hauptverfasser:	Vellopoulou, K, Kourlaba, G, Giannoulia, P, Panagiotidis, P, Maniadakis, N
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute lymphoblastic leukemia Appropriateness Chemotherapy Chromosomes Cost analysis Experts Health care expenditures Induction Intolerance Leukemia Life expectancy Life span Lymphatic leukemia Medical treatment Patients Philadelphia chromosome Prices Quality adjusted life years Quality of life Resistance Sensitivity analysis Stem cells Targeted cancer therapy Transplants & implants Willingness to pay
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!